GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » PE Ratio without NRI
中文

abrdn Life Sciences Investors (abrdn Life Sciences Investors) PE Ratio without NRI : 16.61 (As of Apr. 24, 2024)


View and export this data going back to . Start your Free Trial

abrdn Life Sciences Investors PE Ratio without NRI Definition

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2024-04-24), abrdn Life Sciences Investors's share price is $13.12. abrdn Life Sciences Investors's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79. Therefore, abrdn Life Sciences Investors's PE Ratio without NRI for today is 16.61.

During the past 7 years, abrdn Life Sciences Investors's highest PE Ratio without NRI was 17.92. The lowest was 3.28. And the median was 6.28.

abrdn Life Sciences Investors's EPS without NRI for the six months ended in Sep. 2023 was $-0.48. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79.

As of today (2024-04-24), abrdn Life Sciences Investors's share price is $13.12. abrdn Life Sciences Investors's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79. Therefore, abrdn Life Sciences Investors's PE Ratio for today is 16.61.

Warning Sign:

abrdn Life Sciences Investors stock PE Ratio (=16.65) is close to 10-year high of 17.92

During the past years, abrdn Life Sciences Investors's highest PE Ratio was 17.92. The lowest was 3.28. And the median was 6.28.

abrdn Life Sciences Investors's EPS (Diluted) for the six months ended in Sep. 2023 was $-0.48. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79.

abrdn Life Sciences Investors's EPS (Basic) for the six months ended in Sep. 2023 was $-0.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.79.


abrdn Life Sciences Investors PE Ratio without NRI Historical Data

The historical data trend for abrdn Life Sciences Investors's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors PE Ratio without NRI Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PE Ratio without NRI
Get a 7-Day Free Trial At Loss 3.41 7.82 At Loss 15.78

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.82 At Loss At Loss At Loss 15.78

Competitive Comparison of abrdn Life Sciences Investors's PE Ratio without NRI

For the Asset Management subindustry, abrdn Life Sciences Investors's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors's PE Ratio without NRI Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's PE Ratio without NRI falls into.



abrdn Life Sciences Investors PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

abrdn Life Sciences Investors's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=13.12/0.790
=16.61

abrdn Life Sciences Investors's Share Price of today is $13.12.
For company reported semi-annually, abrdn Life Sciences Investors's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.79.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


abrdn Life Sciences Investors  (NYSE:HQL) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


abrdn Life Sciences Investors PE Ratio without NRI Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's PE Ratio without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Headlines

From GuruFocus

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-15-2022

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-16-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-30-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2021

Tekla Life Sciences Investors Declares Cash Distribution

By Business Wire Business Wire 12-22-2020

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 08-16-2022

Tekla Life Sciences Investors Declares Stock Distribution

By Business Wire Business Wire 08-17-2020

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 03-31-2022